

Dimos Baltas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9202205/publications.pdf>

Version: 2024-02-01

44
papers

761
citations

567281
15
h-index

552781
26
g-index

44
all docs

44
docs citations

44
times ranked

1098
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation—results from a prospective pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1650-1660.	6.4	4
2	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 260-260.	1.6	0
3	The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 120-127.	1.7	3
4	Optimization of hippocampus sparing during whole brain radiation therapy with simultaneous integrated boost—tutorial and efficacy of complete directional hippocampal blocking. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 537-546.	2.0	7
5	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1025-1035.	0.8	12
6	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. <i>Journal of Nuclear Medicine</i> , 2021, 62, 823-828.	5.0	32
7	Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial. <i>Journal of Nuclear Medicine</i> , 2021, 62, 471-478.	5.0	14
8	Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 17, 100-105.	2.9	6
9	FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation Therapy. <i>Cancers</i> , 2021, 13, 814.	3.7	21
10	FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?. <i>Radiation Oncology</i> , 2021, 16, 46.	2.7	24
11	Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. <i>Frontiers in Oncology</i> , 2021, 11, 652678.	2.8	12
12	Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation — Post-hoc analysis from a prospective imaging trial. <i>Radiotherapy and Oncology</i> , 2021, 159, 75-81.	0.6	8
13	Experimental phantom evaluation to identify robust positron emission tomography (PET) radiomic features. <i>EJNMMI Physics</i> , 2021, 8, 46.	2.7	10
14	Source strength determination in iridium-192 and cobalt-60 brachytherapy: A European survey on the level of agreement between clinical measurements and manufacturer certificates. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 108-111.	2.9	2
15	18F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy. <i>Cancers</i> , 2021, 13, 3449.	3.7	19
16	Measuring breathing induced oesophageal motion and its dosimetric impact. <i>Physica Medica</i> , 2021, 88, 9-19.	0.7	0
17	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. <i>Cancers</i> , 2021, 13, 5795.	3.7	19
18	High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. <i>Frontiers in Oncology</i> , 2021, 11, 770959.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition. Radiation Oncology, 2020, 15, 242.	2.7	7
20	Suitability of the microDiamond detector for experimental determination of the anisotropy function of High Dose Rate ¹⁹² Ir brachytherapy sources. Medical Physics, 2020, 47, 5838-5851.	3.0	3
21	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. Theranostics, 2020, 10, 9395-9406.	10.0	16
22	GEC-ESTRO/ACROP recommendations for quality assurance of ultrasound imaging in brachytherapy. Radiotherapy and Oncology, 2020, 148, 51-56.	0.6	16
23	The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. Radiotherapy and Oncology, 2020, 150, 128-135.	0.6	28
24	One-Shot Learning for Deformable Medical Image Registration and Periodic Motion Tracking. IEEE Transactions on Medical Imaging, 2020, 39, 2506-2517.	8.9	66
25	Investigating the role of constrained CVT and CVT in HIPO inverse planning for HDR brachytherapy of prostate cancer. Medical Physics, 2019, 46, 2955-2968.	3.0	4
26	Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. Journal of Contemporary Brachytherapy, 2019, 11, 215-220.	0.9	3
27	Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. Brachytherapy, 2019, 18, 829-834.	0.5	6
28	Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics, 2019, 9, 2595-2605.	10.0	105
29	Monte Carlo and experimental high dose rate ¹⁹² Ir brachytherapy dosimetry with microDiamond detectors. Zeitschrift Fur Medizinische Physik, 2019, 29, 272-281.	1.5	11
30	Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. Radiotherapy and Oncology, 2018, 127, 62-67.	0.6	4
31	Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. Future Oncology, 2018, 14, 737-749.	2.4	2
32	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncology, 2018, 14, 751-769.	2.4	7
33	High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiotherapy and Oncology, 2018, 126, 270-277.	0.6	34
34	CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. Strahlentherapie Und Onkologie, 2018, 194, 1171-1179.	2.0	10
35	Inverse planning and inverse implanting for breast interstitial brachytherapy. Introducing a new anatomy specific breast interstitial template (ASBIT). Radiotherapy and Oncology, 2018, 128, 421-427.	0.6	1
36	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiation Oncology, 2018, 13, 65.	2.7	26

#	ARTICLE	IF	CITATIONS
37	Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiotherapy and Oncology, 2018, 128, 301-307.	0.6	14
38	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiation Oncology, 2018, 13, 81.	2.7	53
39	Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging. Advances in Experimental Medicine and Biology, 2018, 1072, 195-200.	1.6	0
40	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiotherapy and Oncology, 2017, 123, 472-477.	0.6	50
41	Esophagus segmentation in CT via 3D fully convolutional neural network and random walk. Medical Physics, 2017, 44, 6341-6352.	3.0	64
42	The Bebig Valencia-type skin applicators: Dosimetric study and implementation of a dosimetric hybrid technique. Brachytherapy, 2017, 16, 1044-1056.	0.5	3
43	Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols. Physica Medica, 2017, 40, 33-41.	0.7	10
44	Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. Journal of Contemporary Brachytherapy, 2016, 3, 241-248.	0.9	22